AsianScientist (May 8, 2018) – STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), has announced the signing of an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.
Over the years, WuXi STA has established a process development platform with over 1,000 scientists and five sites located in China and the US. WuXi STA’s Jinshan site currently focuses on manufacturing innovative active pharmaceutical ingredients (APIs) and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the US Food and Drug Administration.
The new R&D center is located next to the existing Jinshan drug substance manufacturing site. It will add more than 30,000 square meters of laboratory space and 500 scientists. Upon completion, the new Jinshan campus will be able to offer an integrated one-site solution for partners to push forward innovative APIs and advanced intermediates through preclinical and clinical development to global commercial launch. The new campus will also offer access to many industry-leading technology platforms such as flow chemistry and biocatalysis.
“The new R&D center is a reflection of our commitment to better serve our customers worldwide and support the growth of the local economy as well as the biopharmaceutical ecosystem in Jinshan,” said Dr. Chen Minzhang, CEO of WuXi STA. “As we continuously strengthen the capability and capacity of our platform, we will enable more global partners to shorten the time and lower the cost of new drug development, and improve lives of people around the world.”
Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.